Dalbavancin for the treatment of acute bacterial skin and skin structure infections;Dalbavancina nel trattamento delle infezioni batteriche acute della cute e delle strutture cutanee

Infezioni in Medicina

Volumn 23, Issue 4, 2015, Pages 313-317

  Esposito, Silvano ^a   Noviello, Silvana ^a   Leone, Sebastiano ^a  

^a UNIVERSITY OF SALERNO   (Italy)

Author keywords

Acute bacterial skin and skin structure infections; Dalbavancin; MRSA

Indexed keywords

DALBAVANCIN; GLYCOPEPTIDE; LINEZOLID; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

AGED; BACTERIAL SKIN DISEASE; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GENE EXPRESSION; GLYCOSYLATION; HEMODIALYSIS; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MILD HEPATIC IMPAIRMENT; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CLEARANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN DISEASE; SKIN STRUCTURE INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS ANGINOSUS; STREPTOCOCCUS PYOGENES; VANCOMYCIN RESISTANT ENTEROCOCCUS; ANALOGS AND DERIVATIVES; DOSE RESPONSE; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; MICROBIAL SENSITIVITY TEST; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL INFECTIONS; TEICOPLANIN; TREATMENT OUTCOME;

EID: 84952661898     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Esposito S., Bassetti M., Borre S., et al. Diagnosis and Management of Skin and Soft-Tissue Infections (SSTI): a Literature Review and Consensus Statement on Behalf of the Italian Society of Infectious Diseases and International Society of Chemotherapy. J. Chemother. 23, 251-262, 2011.
2. Esposito S., Leone S., Petta E., Noviello S. Skin and soft tissue infections: classification and epidemiology. Infez. Med. 17 (Suppl. 4), 6-17, 2009.
3. Ray G.T., Suaya J.A., Baxter R. Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based study. BMC. Infect. Dis. 13, 252, 2013.
4. Miller L.G., Eisenberg D.F., Liu H., et al. Incidence of skin and soft tissue infections in ambulatory and inpatient settings, 2005-2010. BMC. Infect. Dis. 15, 362, 2015.
5. Nicastri E., Leone S., Petrosillo N., et al. Decrease of Methicillin Resistant Staphylococcus aureus prevalence after introduction of a surgical antibiotic prophylaxis protocol in an Italian hospital. New. Microbiol. 31, 519-525, 2008.
6. Esposito S., Capuano A., Noviello S., et al. Modification of patients’ endogenous bacterial flora during hospitalisation in a large teaching hospital in Naples. J. Chemother. 15, 568-573, 2003.
7. Esposito S., Ianniello F., Leone S., et al. Surveillance of post-operative infections and management of antibiotic surgical prophylaxis in an Italian region. J. Chemother. 16, 160-165, 2004.
8. Ippolito G., Leone S., Lauria F.N., Nicastri E., Wenzel R.P. Methicillin-Resistant Staphylococcus aureus: the Superbug. Int. J. Infect. Dis. 14 (Suppl. 4), 7-11, 2010.
9. Esposito S., Gioia R., De Simone G., et al. BacterialEpidemiology and Antimicrobial Resistance in the Surgery Wards of a Large Teaching Hospital in Southern Italy. Mediterr. J. Hematol. Infect. Dis. 7, e2015040, 2015.
10. Leone S., Noviello S., Boccia G., De Caro F., Esposito S. Methicillin-resistant Staphylococcus aureus infections: role of daptomycin/β-lactams combination. Infez. Med. 23, 99-104, 2015.
11. Esposito S., Esposito I., Leone S. Considerations on antibiotic therapy duration in community-and hospital-acquired bacterial infections. J. Antimicrob. Chemother. 67, 2570-2575, 2012.
12. Leone S., Rossi M., Bisi L., Gori A., Esposito S. Antimicrobial therapy duration: a major matter in the management of severe infections. Int. J. Antimicrob. Agents. 42, 287-288, 2013.
13. Esposito S., Noviello S., Leone S. Skin and soft tissue infections: current therapeutic options. Infez. Med. 16, 65-73, 2008.
14. Esposito S., Leone S., Noviello S., Ianniello F. Analysis of current guidelines for the treatment of skin and soft tissue infections. Infez. Med. 17 (Suppl. 4), 58-63, 2009.
15. Malabarba A., Goldstein B.P. Origin, structure, and activity in vitro and in vivo of dalbavancin. J. Antimicrob. Chemother. 55 (Suppl. 2), 15-20, 2005.
16. Biedenbach D.J., Bell J.M., Sader H.S., et al. Activities of dalbavancin against a worldwide collection of 81,673 gram positive bacterial isolates. Antimicrob. Agents. Chemother. 53, 1260-1263, 2009.
17. Jones R.N., Stilwell M.G., Sader H.S., et al. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004). Diagnostic. Microb. Infect. Dis. 54, 149-153, 2006.
18. Citron D.M., Tyrrell K.L., Goldstein E.J. Comparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains. Diagn. Microbiol. Infect. Dis. 79, 438-440, 2014.
19. Smith J.R., Roberts K.D., Rybak M.J. Dalbavancin: a novel lipoglycopeptide antibiotic with extended activity against gram-positive infections. Infect. Dis. Ther. 4, 245-258, 2015.
20. Streit J.M., Sader H.S., Fritsche T., Jones R.N. Dalbavancin activity against selected populations of antimicrobial-resistant gram-positive pathogens. Diagn. Microbiol. Infect. Dis. 53, 307-310, 2005.
21. Leighton A., Gottlieb A.B., Dorr M.B., et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob. Agents. Chemother. 48, 940-945, 2004.
22. NDA 021-883 Briefing Document. Durata Therapeutics International B.V. Anti-Infective Drugs Advisory Committee. March 31, 2014.
23. Smith J.R., Roberts K.D., Rybak M.J. Dalbavancin: a novel lipoglycopeptide antibiotic with extended activity against gram-positive infections. Infect. Dis. Ther. 4, 245-258, 2015.
24. Billeter M., Zervos M.J., Chen A.Y., Dalovisio J.R., Kurukularatne C. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin. Infect. Dis. 46, 577-583, 2008.
25. Xydalba. Summary of product characteristics. Retrieved from http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002840/human_med_001848.jsp&mid=WC0b01ac058001d124. Last accessed November 15, 2015.
26. Seltzer E., Dorr M.B., Goldstein B.P., Perry M., Dowell J.A., Henkel T. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin. Infect. Dis. 37, 1298-1303, 2003.
27. Jauregui L.E., Babazadeh S., Seltzer E., et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis. 41, 1407-1415, 2005.
28. Boucher H.W., Wilcox M., Talbot G.H., Puttagunta S., Das A.F., Dunne M.W. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N. Engl. J. Med. 370, 2169-2179, 2014.
29. Esposito S., Leone S., Noviello S., et al. Outpatient parenteral antibiotic therapy in the elderly: an Italian observational multicenter study. J. Chemother. 21, 193-198, 2009.
30. Esposito S., Leone S., Noviello S., Lanniello F., Fiore M. Antibiotic resistance in long-term care facilities. New. Microbiol. 30, 326-331, 2007.
31. Dalvance. Statistical Review and Evaluation. NDA #: 21-883. Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/021883Orig1s000StatR.pdf. Last accessed November 15, 2015.
32. Chen A.Y., Zervos M.J., Vazquez J.A. Dalbavancin: a novel antimicrobial. Int. J. Clin. Pract. 61, 853-863, 2007.
33. Raad I., Darouiche R., Vazquez J., et al. Efficacy and safety of weekly dalbavancin therapy for catheterrelated bloodstream infection caused by gram-positive pathogens. Clin. Infect. Dis. 40, 374-380, 2005.
34. Dryden M.S. Alternative clinical indications for novel antibiotics licensed for skin and soft tissue infection? Curr. Opin. Infect. Dis. 28, 117-124, 2015.
35. Esposito S., Leone S., Bassetti M., et al. Italian guidelines for the diagnosis and infectious disease management of osteomyelitis and prosthetic joint infections in adults. Infection 37, 478-96, 2009.
36. Dunne M.W., Puttagunta S., Sprenger C.R., Rubino C., Van Wart S., Baldassarre J. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob. Agents. Chemother. 59, 1849-1855, 2015.
37. Barnea Y., Lerner A., Aizic A., et al. Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis. J. Antimicrob. Chemother. 2015. pii: dkv357.